Jon Mcclelland Lockard

Array ( [id] => 14182947 [patent_doc_number] => 20190111178 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-18 [patent_title] => METHODS AND COMPOSITIONS FOR THE TREATMENT OF INTERVERTEBRAL DISC HERNIATION [patent_app_type] => utility [patent_app_number] => 16/090936 [patent_app_country] => US [patent_app_date] => 2017-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9451 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16090936 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13234995 [patent_doc_number] => 10130681 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-11-20 [patent_title] => Use of a VEGF antagonist to treat angiogenic eye disorders [patent_app_type] => utility [patent_app_number] => 15/471506 [patent_app_country] => US [patent_app_date] => 2017-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 8958 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 136 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15471506 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13814445 [patent_doc_number] => 10183983 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-01-22 [patent_title] => Nucleic acids encoding fusion proteins comprising PDGF and VEGF binding portions and methods of using thereof [patent_app_type] => utility [patent_app_number] => 15/471725 [patent_app_country] => US [patent_app_date] => 2017-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 13 [patent_no_of_words] => 27274 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15471725 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12927958 [patent_doc_number] => 09828431 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-11-28 [patent_title] => Use of IL-31RA monoclonal antibodies for treating neuronal inflammation [patent_app_type] => utility [patent_app_number] => 15/461090 [patent_app_country] => US [patent_app_date] => 2017-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15751 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15461090 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16743287 [patent_doc_number] => 10968262 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-06 [patent_title] => Methods of increasing sarcolemmal utrophin [patent_app_type] => utility [patent_app_number] => 15/459338 [patent_app_country] => US [patent_app_date] => 2017-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 12 [patent_no_of_words] => 20637 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15459338 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12945688 [patent_doc_number] => 09834602 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-12-05 [patent_title] => Use of IL-31 monoclonal antibodies for treating neuronal inflammation [patent_app_type] => utility [patent_app_number] => 15/459901 [patent_app_country] => US [patent_app_date] => 2017-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15099 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15459901 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11956440 [patent_doc_number] => 20170260591 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-14 [patent_title] => 'DDR2 MUTATIONS AS TARGETABLE FEATURES OF MELANOMA OR BASAL CELL CARCINOMA' [patent_app_type] => utility [patent_app_number] => 15/455509 [patent_app_country] => US [patent_app_date] => 2017-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 11003 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15455509 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14102345 [patent_doc_number] => 20190092848 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-28 [patent_title] => Methods of treating bone diseases, disorders and/or injuries and reagents therefor [patent_app_type] => utility [patent_app_number] => 16/081081 [patent_app_country] => US [patent_app_date] => 2017-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27455 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16081081 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16443713 [patent_doc_number] => 10835617 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-17 [patent_title] => VEGF antibody-drug conjugates [patent_app_type] => utility [patent_app_number] => 16/072415 [patent_app_country] => US [patent_app_date] => 2017-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 3247 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16072415 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12144843 [patent_doc_number] => 09879084 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-01-30 [patent_title] => 'Modified immunoglobulin molecules that specifically bind human VEGF and DLL4' [patent_app_type] => utility [patent_app_number] => 15/401543 [patent_app_country] => US [patent_app_date] => 2017-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 14 [patent_no_of_words] => 51258 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15401543 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16832146 [patent_doc_number] => 11008387 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-18 [patent_title] => Antibody inhibiting binding of VEGF to NRP1 [patent_app_type] => utility [patent_app_number] => 16/067958 [patent_app_country] => US [patent_app_date] => 2017-01-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 17517 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16067958 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14116935 [patent_doc_number] => 10245308 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-02 [patent_title] => Combination therapy utilizing P2X7 peptides [patent_app_type] => utility [patent_app_number] => 15/399337 [patent_app_country] => US [patent_app_date] => 2017-01-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 2 [patent_no_of_words] => 11437 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 156 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15399337 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17420144 [patent_doc_number] => 11253573 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-22 [patent_title] => Compositions and methods for treating heart failure [patent_app_type] => utility [patent_app_number] => 15/397623 [patent_app_country] => US [patent_app_date] => 2017-01-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8286 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15397623 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11864800 [patent_doc_number] => 20170232085 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-17 [patent_title] => 'COMPANION ANIMAL TREATMENTS' [patent_app_type] => utility [patent_app_number] => 15/387421 [patent_app_country] => US [patent_app_date] => 2016-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 15056 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15387421 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11590885 [patent_doc_number] => 20170115296 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-27 [patent_title] => 'TRACEABILITY OF CELLULAR CYCLE ANOMALIES TARGETING ONCOLOGY AND NEURODEGENERATION' [patent_app_type] => utility [patent_app_number] => 15/383251 [patent_app_country] => US [patent_app_date] => 2016-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 80 [patent_figures_cnt] => 80 [patent_no_of_words] => 17416 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15383251 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16414532 [patent_doc_number] => 10822408 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-03 [patent_title] => PACAP antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/063152 [patent_app_country] => US [patent_app_date] => 2016-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 9 [patent_no_of_words] => 30592 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 163 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16063152 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17635033 [patent_doc_number] => 11345746 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-31 [patent_title] => Fully human antibody specifically inhibiting Connexin 26 [patent_app_type] => utility [patent_app_number] => 15/781463 [patent_app_country] => US [patent_app_date] => 2016-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 10 [patent_no_of_words] => 4439 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15781463 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11714912 [patent_doc_number] => 20170183411 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-29 [patent_title] => 'METHODS AND COMPOSITIONS TO REGULATE HEPCIDIN EXPRESSION' [patent_app_type] => utility [patent_app_number] => 15/375491 [patent_app_country] => US [patent_app_date] => 2016-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 21686 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15375491 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13729871 [patent_doc_number] => 20180369403 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-27 [patent_title] => LGR4 SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF THEIR USE [patent_app_type] => utility [patent_app_number] => 16/062386 [patent_app_country] => US [patent_app_date] => 2016-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12555 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16062386 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13603971 [patent_doc_number] => 20180353534 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-13 [patent_title] => METHODS FOR TREATING SARCOPENIA AND FRAILTY [patent_app_type] => utility [patent_app_number] => 15/778791 [patent_app_country] => US [patent_app_date] => 2016-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11004 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15778791 [rel_patent_id] =>[rel_patent_doc_number] =>)